Drug-resistant gonorrhea has been an escalating global public health concern for decades, but the pace of resistance emergence rarely makes headlines until a front-line treatment fails. The 2024 GRASP data from England and Wales offers a granular snapshot of where that trajectory stands — with one finding in particular warranting serious attention from clinicians and epidemiologists alike.
Analysis of 1,512 consecutive Neisseria gonorrhoeae isolates collected across 22 sentinel clinics during August–September 2024 reveals a mixed but cautionary picture. The critical first-line injectable treatment, ceftriaxone, remains largely effective, with only 1.7% of isolates showing reduced susceptibility (MIC >0.03 mg/L). The oral alternative cefixime fared slightly worse, with 3.1% resistance. Azithromycin showed reduced susceptibility in 13.6% of isolates, though the majority sat just marginally above the epidemiological cutoff at MIC 2 mg/L. Most strikingly, penicillin resistance jumped to 25.9% — nearly double the proportion recorded in 2023 — and tetracycline resistance stood at 90.6%. Ciprofloxacin resistance, predicted genomically, actually declined from 58.7% to 46.4%, a rare piece of favorable news.
This surveillance dataset is among the most rigorously structured gonococcal resistance programs globally, lending its findings considerable credibility. The near-doubling of penicillin resistance in a single year is epidemiologically unusual and, while penicillin is no longer a recommended gonorrhea treatment in the UK, the trend signals ongoing horizontal gene transfer and mobile resistance element activity within circulating strains — a harbinger for future threats to active agents. The continued dominance of ceftriaxone susceptibility is reassuring but fragile; globally, ceftriaxone treatment failures have already been documented. The modest azithromycin drift above ECOFF, even without frank high-level resistance, complicates any future role for combination regimens. As a sentinel, time-limited cross-sectional sample, these figures reflect August–September transmission networks and may not capture full annual diversity. Nonetheless, this report reinforces that gonorrhea's resistance evolution is neither linear nor predictable, demanding continuous molecular and phenotypic surveillance.